Literature DB >> 28950303

Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients.

M V Heppt1, M Schlaak2, T K Eigentler3, K C Kähler4, F Kiecker5, C Loquai6, F Meier7, D Tomsitz8, N Brenner2, A C Niesert1, R Thonke6, A Hauschild4, C Berking1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28950303     DOI： 10.1093/annonc/mdx538

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  19 in total

1.  Robust expansion of HIV CAR T cells following antigen boosting in ART-suppressed nonhuman primates.

Authors:  Blake J Rust; Leslie S Kean; Lucrezia Colonna; Katherine E Brandenstein; Nikhita H Poole; Willimark Obenza; Mark R Enstrom; Colby R Maldini; Gavin I Ellis; Christine M Fennessey; Meei-Li Huang; Brandon F Keele; Keith R Jerome; James L Riley; Hans-Peter Kiem; Christopher W Peterson
Journal:  Blood       Date:  2020-10-08       Impact factor: 22.113

Review 2.  Checkpoint Inhibitors.

Authors:  Lucie Heinzerling; Enrico N de Toni; Georg Schett; Gheorghe Hundorfean; Lisa Zimmer
Journal:  Dtsch Arztebl Int       Date:  2019-02-22       Impact factor: 5.594

Review 3.  Cancer immunotherapy of patients with HIV infection.

Authors:  M Gonzalez-Cao; J Martinez-Picado; N Karachaliou; R Rosell; A Meyerhans
Journal:  Clin Transl Oncol       Date:  2018-11-17       Impact factor: 3.405

4.  Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Christopher K Bichakjian; Thomas Olencki; Sumaira Z Aasi; Murad Alam; James S Andersen; Rachel Blitzblau; Glen M Bowen; Carlo M Contreras; Gregory A Daniels; Roy Decker; Jeffrey M Farma; Kris Fisher; Brian Gastman; Karthik Ghosh; Roy C Grekin; Kenneth Grossman; Alan L Ho; Karl D Lewis; Manisha Loss; Daniel D Lydiatt; Jane Messina; Kishwer S Nehal; Paul Nghiem; Igor Puzanov; Chrysalyne D Schmults; Ashok R Shaha; Valencia Thomas; Yaohui G Xu; John A Zic; Karin G Hoffmann; Anita M Engh
Journal:  J Natl Compr Canc Netw       Date:  2018-06       Impact factor: 12.693

Review 5.  Immunotherapy use outside clinical trial populations: never say never?

Authors:  K Rzeniewicz; J Larkin; A M Menzies; S Turajlic
Journal:  Ann Oncol       Date:  2021-03-24       Impact factor: 51.769

Review 6.  Immune Checkpoint Inhibitors in Melanoma and HIV Infection.

Authors:  Antonio Marra; Giosuè Scognamiglio; Ilaria Peluso; Gerardo Botti; Celeste Fusciello; Amelia Filippelli; Paolo A Ascierto; Stefano Pepe; Francesco Sabbatino
Journal:  Open AIDS J       Date:  2017-11-14

Review 7.  The Role of Immunomodulatory Receptors in the Pathogenesis of HIV Infection: A Therapeutic Opportunity for HIV Cure?

Authors:  Hui Chen; Maha Moussa; Marta Catalfamo
Journal:  Front Immunol       Date:  2020-07-02       Impact factor: 7.561

8.  Complete response to ipilimumab and nivolumab therapy in a patient with extensive extrapulmonary high-grade small cell carcinoma of the pancreas and HIV infection.

Authors:  Muhammad Husnain; Wungki Park; Juan Carlos Ramos; Thomas E Johnson; Joseph Chan; Arvind Dasari; Raja Mudad; Peter J Hosein
Journal:  J Immunother Cancer       Date:  2018-07-09       Impact factor: 13.751

Review 9.  Immunotherapy and Gene Therapy for Oncoviruses Infections: A Review.

Authors:  Nathália Alves Araújo de Almeida; Camilla Rodrigues de Almeida Ribeiro; Jéssica Vasques Raposo; Vanessa Salete de Paula
Journal:  Viruses       Date:  2021-05-02       Impact factor: 5.048

Review 10.  Checkpoint inhibitor use in two heart transplant patients with metastatic melanoma and review of high-risk populations.

Authors:  Michael J Grant; Nicholas DeVito; April K S Salama
Journal:  Melanoma Manag       Date:  2018-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.